Recipharm releases the lock-up on 1.3 million B-shares related to shares to be issued upon conversion of convertible bonds

In connection with the acquisition of Corvette Pharmaceutical Services Group
completed on October 1, 2014, Recipharm AB (publ) (“Recipharm”) issued
convertible bonds with a nominal value of EUR 50 million as part of the
financing of the acquisition. The convertible bonds can be converted into up to
5,030,549 class B-shares. The holders of the convertible bonds have agreed to a
lock-up in respect of the new shares issued upon conversion until 14 February,
2015.
Recipharm has received a request and has released the lock-up on 1.3 million B
-shares related to shares to be issued upon conversion of the convertible bonds.
The release of the lock-up has been granted to facilitate the sale of 1.3
million class B-shares to Första AP-fonden.

Thomas Eldered, CEO:
“We are pleased that there is continued strong interest in Recipharm and note
that Första AP-fonden, through this transaction, will increase its shareholding
from 0.7 million B-shares to 2 million B-shares, corresponding to 4.8 percent of
the total capital in Recipharm”.

For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 00
Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
NASDAQ Stockholm. This information was submitted for publication on 21st January
2015 at 8:30 am CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden employing some
2,200 employees. Recipharm offers manufacturing services of pharmaceuticals in
various dosage forms, production of clinical trial material including API and
pharmaceutical product development. Recipharm manufactures more than 400
different products to customers ranging from Big Pharma through to smaller
research- and development companies. Recipharm’s turnover is approximately SEK
3.3 billion and the Company operates development and manufacturing facilities in
Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered
in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on NASDAQ
Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com